Quantitative measurement of total erbB2 (H2T), p110 t-erbB2, and erbB2:erbB3 heterodimer (H23D) expression implicates p110 t-erbB2 in malignant progression from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC)